Event detail
The discovery of Kisqali® (ribociclib), a CDK4/6 inhibitor for the treatment of breast cancer
Seminar | March 19 | 1:30-2:30 p.m. | 775 Tan Hall
Dr. Christopher Brain, Novartis
seminarcoordinator-cchem@berkeley.edu, 510-643-0572
Seminar | March 19 | 1:30-2:30 p.m. | 775 Tan Hall
Dr. Christopher Brain, Novartis
seminarcoordinator-cchem@berkeley.edu, 510-643-0572